{
  "image_filename": "table_p11_det_10_013.png",
  "image_path": "Liu_et_al.__2024_/extracted/figures/table_p11_det_10_013.png",
  "image_type": "Table",
  "page_number": 11,
  "block_id": "det_10_013",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "A table summarizing demographic characteristics and prior influenza vaccination history for four vaccine groups (Fluzone IIV4, Fluarix IIV4, ccIIV4, RIV4), including sample size, mean age, age groups, sex, race/ethnicity, site distribution, and prior vaccination rates. The table only presents demographic and vaccination history data and does not include any immunogenicity or cross-protection outcomes, so it does not support the claim. Note: No immunologic or efficacy data are shown in this table; it is limited to baseline characteristics.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table summarizing demographic characteristics and prior influenza vaccination history for four vaccine groups (Fluzone IIV4, Fluarix IIV4, ccIIV4, RIV4), including sample size, mean age, age groups, sex, race/ethnicity, site distribution, and prior vaccination rates.",
    "evidence_found": null,
    "reasoning": "The table only presents demographic and vaccination history data and does not include any immunogenicity or cross-protection outcomes, so it does not support the claim.",
    "confidence_notes": "No immunologic or efficacy data are shown in this table; it is limited to baseline characteristics."
  }
}